Last reviewed · How we verify
Armour Thyroid
Armour Thyroid replaces deficient thyroid hormones by providing a combination of T4 (levothyroxine) and T3 (liothyronine) derived from desiccated porcine thyroid tissue.
Armour Thyroid replaces deficient thyroid hormones by providing a combination of T4 (levothyroxine) and T3 (liothyronine) derived from desiccated porcine thyroid tissue. Used for Hypothyroidism (primary, secondary, and tertiary), Myxedema.
At a glance
| Generic name | Armour Thyroid |
|---|---|
| Also known as | AGN-282176, Desiccated thyroid extract, AGN-204771 |
| Sponsor | AbbVie |
| Drug class | Thyroid hormone replacement therapy |
| Target | Thyroid hormone receptors (TR-alpha and TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Armour Thyroid is a natural desiccated thyroid extract containing both thyroxine (T4) and triiodothyronine (T3) in a ratio approximating the natural thyroid secretion. These hormones bind to thyroid hormone receptors in target tissues, increasing metabolic rate, thermogenesis, and protein synthesis. It is used as replacement therapy in hypothyroidism to restore normal thyroid hormone levels and alleviate symptoms of thyroid deficiency.
Approved indications
- Hypothyroidism (primary, secondary, and tertiary)
- Myxedema
Common side effects
- Tachycardia
- Palpitations
- Tremor
- Anxiety
- Insomnia
- Heat intolerance
- Weight loss
- Headache
Key clinical trials
- Natural History Study of Children and Adults With Medullary Thyroid Cancer
- Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (PHASE2)
- Natural History of Thyroid Function Disorders
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
- Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Application and Evaluation of Vision-LSTM Modeling in Diagnostic Ultrasound Imaging of TI-RADS Category 4b Thyroid Nodules
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Armour Thyroid CI brief — competitive landscape report
- Armour Thyroid updates RSS · CI watch RSS
- AbbVie portfolio CI